Santo Therapeutics and PolyGene officially signed a strategic cooperation framework agreement to initiate comprehensive and deep collaboration in the field of gene therapy delivery technologies. The partnership centers on HPAE non‑viral delivery vectors, the novel BrPERfect transfection reagent platform, and integration with Santo’s fifth‑generation lentiviral vector platform (STLenti), with type 1 neurofibromatosis (NF1) as the lead indication.
Partnership Snapshot
| Item | Detail |
|---|---|
| Parties | Santo Therapeutics & PolyGene |
| Agreement Type | Strategic cooperation framework agreement |
| Signing Date | 16 September 2026 |
| Field | Gene therapy delivery technologies |
| Lead Indication | Type 1 neurofibromatosis (NF1) – cutaneous gene therapy |
| Core Platforms | HPAE non‑viral delivery vectors; BrPERfect transfection reagent; STLenti lentiviral vector (5th generation) |
Technology Stack & Mechanism
- HPAE Delivery Vectors: PolyGene’s proprietary hyperbranched poly(beta‑amino ester) non‑viral vectors encapsulate DNA/RNA cargo for precise local dermal administration targeting lesion cells — enabling a topical skin therapy approach.
- BrPERfect Transfection Reagent: A novel transfection platform developed on the basis of HPAE materials, positioned to improve nucleic‑acid delivery efficiency.
- STLenti Lentiviral Platform: Santo Therapeutics’ fifth‑generation lentiviral vector system, serving as the viral vector backbone in the joint optimization work.
- Joint Engineering Objective: The two companies will systematically optimize transfection efficiency and cell‑adaptation parameters and co‑iterate the viral packaging process, aiming to raise the expression ceiling and quality of viral vectors.
Development Program – NF1 Cutaneous Gene Therapy
- Target Disease: Type 1 neurofibromatosis (NF1), a genetic disorder associated with cutaneous neurofibroma lesions.
- Therapeutic Concept: Innovative cutaneous gene therapy regimens delivering DNA/RNA directly to lesion cells via HPAE‑based topical administration, pursuing localized precision rather than systemic exposure.
- Program Stage: Collaboration initiated at framework‑agreement level; development milestones and timelines not disclosed.
- Financial Terms: Deal value and cost‑sharing arrangements not disclosed.
Market Impact & Outlook
- Delivery‑Centric Strategy: By pairing non‑viral HPAE vectors with lentiviral technology, the alliance addresses one of gene therapy’s core bottlenecks — efficient, targeted delivery — across both topical and viral‑manufacturing modalities.
- Differentiated Route: A topical dermal gene therapy for NF1 lesions would offer a potentially less invasive alternative to systemic or surgical approaches in dermatologic genetic disease.
- Manufacturing Upside: Joint iteration of the viral packaging process targets higher vector expression ceilings and quality, a meaningful lever for lentiviral‑based pipeline economics.
- Pipeline Implications: The framework agreement leaves room for expansion beyond NF1 into additional gene therapy delivery applications as the platforms mature.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the Santo Therapeutics–PolyGene collaboration, platform optimization plans, and clinical development expectations for NF1 cutaneous gene therapy. Actual results may differ due to risks including technical feasibility, preclinical and clinical outcomes, intellectual‑property considerations, regulatory review, and the evolution of the partnership under the framework agreement.-Fineline Info & Tech
